AzarGen is a biotechnology company utilising advanced genetic engineering and synthetic biology techniques to express biopharmaceutical compounds of high value.Our focus is to use plants as bioreactors to develop a pipeline of novel and patentable compounds with special emphasis on complex therapeutic proteins.
AzarGen is proving the viability of its plant-based expression platform through a lead candidate, being a recombinant human therapeutic protein. AzarGen’s product is expected to increase the survivability of premature-born infants in the developed and developing world with higher clinical efficiency and at lower cost.